Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Parenteral application of NADH in Parkinson's disease: clinical improvement partially due to stimulation of endogenous levodopa biosynthesis.

Kuhn W, Müller T, Winkel R, Danielczik S, Gerstner A, Häcker R, Mattern C, Przuntek H.

J Neural Transm (Vienna). 1996;103(10):1187-93.

PMID:
9013405
2.

Is NADH effective in the treatment of Parkinson's disease?

Swerdlow RH.

Drugs Aging. 1998 Oct;13(4):263-8. Review.

PMID:
9805207
3.

Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.

Najib J.

Clin Ther. 2001 Jun;23(6):802-32; discussion 771. Review.

PMID:
11440283
4.

[Treatment for advanced Parkinson's disease with intestinal levodopa/carbidopa gel: review of efficacy and safety].

Timofeeva AA.

Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(11):145-51. Review. Russian.

PMID:
25629138
5.

Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.

Lees AJ, Tolosa E, Olanow CW.

Mov Disord. 2015 Jan;30(1):19-36. doi: 10.1002/mds.26120. Epub 2014 Dec 8. Review.

PMID:
25488030
6.

[Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? No].

Friedman A.

Neurol Neurochir Pol. 2007 Mar-Apr;41(2 Suppl 1):S10-3. Review. Polish.

PMID:
17941453
7.

Levodopa infusion therapy in Parkinson disease: state of the art in 2004.

Nyholm D, Aquilonius SM.

Clin Neuropharmacol. 2004 Sep-Oct;27(5):245-56. Review.

PMID:
15602106

Supplemental Content

Support Center